Kahimmune Therapeutics

Kahimmune Therapeutics signs agreement for scientific collaboration with Gustave Roussy

Agreement will enable selection of Kahimmune’s first companion neoantigen therapy candidate against colorectal cancer and pancreatic cancer, with financial support from Bpifrance   Kahimmune exploits dark genome to develop next-generation immuno-oncology therapies. 18 April 2026 -- Avignon, France -- Kahimmune Therapeutics, a biotechnology company developing next-generation immuno-oncology therapies, today announces the signing of an agreement...
2 Avenue Du Blanchissage, 84000 Avignon, France